Literature DB >> 2829264

Effects of yohimbine in obsessive compulsive disorder.

S A Rasmussen1, W K Goodman, S W Woods, G R Heninger, D S Charney.   

Abstract

The alpha 2-adrenergic receptor antagonist yohimbine was administered to 12 drug-free patients with obsessive compulsive disorder (OCD) and to 12 healthy subjects. Changes in behavior, cardiovascular symptoms, and in plasma levels of cortisol and the norepinephrine metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG), were assessed. Yohimbine had no significant effect on OCD symptoms. The OCD patients did not differ from healthy controls in their behavioral and MHPG response to yohimbine. In contrast to healthy subjects, OCD patients, like previous reports of depressed and panic disorders patients, had an increased cortisol response to yohimbine. These data suggest it is unlikely that abnormal noradrenergic function plays a primary role in the pathogenesis of OCD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2829264     DOI: 10.1007/BF00187248

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Dissociation of the effects of scopolamine and d-amphetamine on a spontaneous alternation task.

Authors:  L Kokkinidis; H Anisman
Journal:  Pharmacol Biochem Behav       Date:  1976-09       Impact factor: 3.533

2.  Catecholamine receptors on locus coeruleus neurons: pharmacological characterization.

Authors:  J M Cedarbaum; G K Aghajanian
Journal:  Eur J Pharmacol       Date:  1977-08-15       Impact factor: 4.432

Review 3.  Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs.

Authors:  W K Goodman; D S Charney
Journal:  J Clin Psychiatry       Date:  1985-10       Impact factor: 4.384

4.  Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride.

Authors:  J W Knesevich
Journal:  Am J Psychiatry       Date:  1982-03       Impact factor: 18.112

5.  Plasma and CSF MHPG in normals [proceedings].

Authors:  D C Jimerson; J C Ballenger; C R Lake; R M Post; F K Goodwin; I J Kopin
Journal:  Psychopharmacol Bull       Date:  1981-01

6.  Clinical characteristics and family history in DSM-III obsessive-compulsive disorder.

Authors:  S A Rasmussen; M T Tsuang
Journal:  Am J Psychiatry       Date:  1986-03       Impact factor: 18.112

7.  Growth hormone response to clonidine in obsessive-compulsive patients.

Authors:  L J Siever; T R Insel; D C Jimerson; C R Lake; T W Uhde; J Aloi; D L Murphy
Journal:  Br J Psychiatry       Date:  1983-02       Impact factor: 9.319

8.  Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective.

Authors:  J F Leckman; J Detlor; D F Harcherik; S Ort; B A Shaywitz; D J Cohen
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

9.  Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates.

Authors:  J D Elsworth; D E Redmond; R H Roth
Journal:  Brain Res       Date:  1982-03-04       Impact factor: 3.252

10.  Presence of free, sulfate and glucuronide conjugated 3-methoxy-4-hydroxyphenylglycol (MHPG) in human brain, cerebrospinal fluid and plasma.

Authors:  F Karoum; J Moyer-Schwing; S G Potkin; R J Wyatt
Journal:  Brain Res       Date:  1977-04-15       Impact factor: 3.252

View more
  4 in total

1.  Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder.

Authors:  D S Charney; R B Innis; R S Duman; S W Woods; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Pentagastrin has panic-inducing properties in obsessive compulsive disorder.

Authors:  A S de Leeuw; J A Den Boer; B R Slaap; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

3.  Melatonin responses to clonidine and yohimbine challenges.

Authors:  S H Kennedy; W Gnam; E Ralevski; G M Brown
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

4.  Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers.

Authors:  T Hedner; B Edgar; L Edvinsson; J Hedner; B Persson; A Pettersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.